Nivolumab: all 1,113 studies that test it

Page 7 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.

• NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHNCompletedNCT05802290Phase 3
• Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal MetastasisActive, not recruitingNCT05802056Phase 1
• Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.Active, not recruitingNCT05788081Phase 2
• Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNWithdrawnNCT05743270Phase 2
• Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin LymphomaActive, not recruitingNCT05723055Phase 2
• Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic CancerCompletedNCT05721846Phase 1
• Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the LungWithdrawnNCT05717140Phase 1
• Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesCompletedNCT05704933Early Phase 1
• Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)Active, not recruitingNCT05696548Phase 2
• DUMAS: Neo-Adjuvant Immunotherapy for Pancoast TumorsActive, not recruitingNCT05684276Phase 2
• Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05678673Phase 3
• Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationActive, not recruitingNCT05672173Phase 2
• Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCSuspendedNCT05663710Phase 1/2
• Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin LymphomaStatus unknownNCT05660993Phase 2
• A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid TumorsCompletedNCT05625412Phase 1
• Intrathecal Double Checkpoint InhibitionActive, not recruitingNCT05598853Phase 1
• Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerCompletedNCT05535569Phase 1/2
• Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT05502315Phase 2
• Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Active, not recruitingNCT05501054Phase 1/2
• Study of Relatlimab in Combination With Nivolumab in Chinese ParticipantsCompletedNCT05498480Phase 1
• A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWithdrawnNCT05496192Phase 2
• Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 StudyActive, not recruitingNCT05491616Phase 2
• Nivolumab and All-trans Retinoic Acid for Pancreatic CancerStatus unknownNCT05482451Early Phase 1
• Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionActive, not recruitingNCT05480384Phase 2
• Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabWithdrawnNCT05472623Phase 2
• Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck CancerWithdrawnNCT05472506Phase 1
• Neoadjuvant Anti-PD1 in HCCCompletedNCT05471674Phase 2
• Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantWithdrawnNCT05457959Phase 1
• Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerSuspendedNCT05445609Phase 2
• Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic CancerTerminatedNCT05435053Phase 2
• A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous MelanomaActive, not recruitingNCT05418972Phase 2
• Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsActive, not recruitingNCT05407441Phase 1/2
• Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedNCT05394740Phase 1/2
• Fedratinib in Combination With NivolumabCompletedNCT05393674Phase 2
• Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at LymphodepletionStatus unknownNCT05385263Phase 2
• SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationTerminatedNCT05375084Phase 1
• A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128Active, not recruitingNCT05354102Phase 1
• Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline TherapyActive, not recruitingNCT05352828Phase 1
• Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaActive, not recruitingNCT05347212Phase 2
• Efficacy of VTP-300 in Chronic Hepatitis B InfectionCompletedNCT05343481Phase 2
• Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesTerminatedNCT05341349Phase 1
• Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant LesionsActive, not recruitingNCT05327270Phase 1
• Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationActive, not recruitingNCT05308446Phase 2
• Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid TumorsCompletedNCT05302921Phase 2
• CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaActive, not recruitingNCT05289193Phase 2
• NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasCompletedNCT05262556Phase 1
• Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerActive, not recruitingNCT05239533Phase 2
• A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLCStatus unknownNCT05236608Phase 1/2
• Nivolumab for Recurrent/Metastatic CarcinosarcomaStatus unknownNCT05224999Phase 2
• Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial CancerCompletedNCT05219435Phase 2
• CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyActive, not recruitingNCT05215470Phase 2
• Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCCStatus unknownNCT05213312Phase 2/3
• A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabTerminatedNCT05199285Phase 2
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
• GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingNCT05178043Phase 2
• Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA MeasurementsStatus unknownNCT05175235Phase 1/2
• Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)CompletedNCT05169957Phase 1
• CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedActive, not recruitingNCT05162976Phase 1
• Neoadjuvant Nivolumab for Upper Tract Urothelial CarcinomaStatus unknownNCT05160285Phase 2
• Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract CancersWithdrawnNCT05153304Phase 1/2
• EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCActive, not recruitingNCT05150236Phase 2
• A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingNCT05144854Phase 3
• A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsCompletedNCT05136677Phase 2
• Neo-NTP-CRT for Locally Advanced ESCCStatus unknownNCT05130684Phase 2
• Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.TerminatedNCT05116917Phase 2
• Brazilian Lung Immunotherapy StudyCompletedNCT05081674Phase 2
• A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyWithdrawnNCT05039736Phase 2
• A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Status unknownNCT05027204Phase 1/2
• Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyWithdrawnNCT05022394Phase 1/2
• Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesActive, not recruitingNCT05012254Phase 2
• Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal MelanomaCompletedNCT05004025Phase 1
• Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOmaCompletedNCT04988841Phase 2
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaCompletedNCT04987203Phase 3
• Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric CancerCompletedNCT04984733Phase 2
• A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04981899Phase 1/2
• Combination Immunotherapy in Rare Cancers Under InvesTigationActive, not recruitingNCT04969887Phase 2
• Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic MelanomaTerminatedNCT04967196Phase 1
• Study of Nivolumab-Ipilimumab and cfDNA in Lung CancerTerminatedNCT04966676Phase 2
• Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver CancerWithdrawnNCT04965714Phase 2
• Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerActive, not recruitingNCT04963283Phase 2
• Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 ExpressionActive, not recruitingNCT04957615Phase 2
• A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and NivolumabWithdrawnNCT04955262Phase 1
• Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic CancerCompletedNCT04953962Phase 2
• ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2
• A Study of BMS-986416 With and Without Nivolumab in Select Solid TumorsCompletedNCT04943900Phase 1
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 2
• NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingNCT04930783Phase 1
• Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerActive, not recruitingNCT04929028Phase 2
• REduced Frequency ImmuNE Checkpoint Inhibition in CancersStatus unknownNCT04913025Phase 2
• Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT04910347Phase 2
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedNCT04904302Phase 2
• Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTIONTerminatedNCT04901988Phase 2/3
• CIVO Intratumoural Microdosing of Anti-Cancer Therapies in AustraliaWithdrawnNCT04891718Early Phase 1
• PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedNCT04887194Phase 1
• Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)Active, not recruitingNCT04884282Phase 2
• Pre-operative Immunotherapy in Stage II-III Urothelial CancerCompletedNCT04871594Phase 1
• Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2
• Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck CaActive, not recruitingNCT04848116Phase 2
• A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04845139Not applicable
• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingNCT04835805Phase 1

← Nivolumab overview